137 related articles for article (PubMed ID: 37722984)
1. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
[TBL] [Abstract][Full Text] [Related]
4. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
[TBL] [Abstract][Full Text] [Related]
5. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
7. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
[No Abstract] [Full Text] [Related]
8. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
[TBL] [Abstract][Full Text] [Related]
9. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Bosma NA; Warkentin MT; Gan CL; Karim S; Heng DYC; Brenner DR; Lee-Ying RM
Eur Urol Open Sci; 2022 Mar; 37():14-26. PubMed ID: 35128482
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
Elaidi R; Phan L; Borchiellini D; Barthelemy P; Ravaud A; Oudard S; Vano Y
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32599839
[TBL] [Abstract][Full Text] [Related]
14. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Numakura K; Sekine Y; Hatakeyama S; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Kashima S; Yamamto R; Nara T; Akashi H; Tabata R; Sato S; Saito M; Narita S; Ohyama C; Habuchi T
Cancer Med; 2023 Aug; 12(16):16837-16845. PubMed ID: 37403728
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T
Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O; Hasanov E; Wilson NR; Araujo J; Wang J; Campbell MT; Goswami S; Shah AY; Gao J; Msaouel P; Tannir NM
Int J Cancer; 2021 Jul; 149(2):387-393. PubMed ID: 33739450
[TBL] [Abstract][Full Text] [Related]
20. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
Betts KA; Gao S; Ray S; Schoenfeld AJ
Future Oncol; 2024 Apr; 20(13):851-862. PubMed ID: 38240151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
